Contineum Therapeutics, Inc.
CTNMAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Nov 4, 2026 | Stifel Nicolaus | Paul Matteis | $23.00(+138%) | $9.65 | StreetInsider |
| Sep 30, 2026 | Stifel Nicolaus | Paul Matteis | $28.00(+117%) | $12.92 | StreetInsider |
| Sep 27, 2026 | Morgan Stanley | Sean Laaman | $17.00(+35%) | $12.56 | TheFly |
| Sep 15, 2026 | Robert W. Baird | $19.00(+28%) | $14.82 | TheFly | |
| May 14, 2026 | Morgan Stanley | $16.00(+13%) | $14.15 | TheFly | |
| Jan 8, 2026 | Morgan Stanley | $14.00(+46%) | $9.56 | TheFly | |
| Nov 24, 2025 | Robert W. Baird | $14.00(+28%) | $10.95 | TheFly | |
| Nov 21, 2025 | RBC Capital | Brian Abrahams | $22.00(+80%) | $12.22 | TheFly |
| Sep 25, 2025 | Leerink Partners | $20.00(+84%) | $10.86 | TheFly | |
| Mar 7, 2025 | Robert W. Baird | $16.00(+136%) | $6.77 | TheFly | |
| Oct 21, 2024 | Robert W. Baird | Joel Beatty | $32.00(+99%) | $16.07 | StreetInsider |
| Apr 30, 2024 | RBC Capital | Brian Abrahams | $30.00(+88%) | $16.00 | TheFly |
| Apr 30, 2024 | Stifel Nicolaus | Paul Matteis | $29.00(+81%) | $16.00 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Jones Trading | maintain | Buy | Oct 15, 2026 |
| Baird | downgrade | Outperform →Neutral | Oct 14, 2026 |
| Morgan Stanley | maintain | Equal Weight | Sep 28, 2026 |
| Jones Trading | maintain | Buy | Sep 15, 2026 |
| Baird | maintain | Outperform | Sep 15, 2026 |
| RBC Capital | maintain | Outperform | Jul 31, 2026 |
| Morgan Stanley | maintain | Equal Weight | May 14, 2026 |
| Baird | maintain | Outperform | Mar 6, 2026 |
| Morgan Stanley | downgrade | Overweight →Equal Weight | Jan 8, 2026 |
| Baird | maintain | Outperform | Nov 24, 2025 |
| RBC Capital | maintain | Outperform | Nov 21, 2025 |
| Morgan Stanley | maintain | Overweight | Aug 18, 2025 |
| Morgan Stanley | maintain | Overweight | May 19, 2025 |
| RBC Capital | maintain | Outperform | May 15, 2025 |
| Baird | maintain | Outperform | Mar 7, 2025 |
| RBC Capital | maintain | Outperform | Jan 9, 2025 |
| RBC Capital | maintain | Outperform | Nov 7, 2024 |
| RBC Capital | maintain | Outperform | Aug 14, 2024 |
Earnings History
Next report: Mar 4, 2027 · EPS est. $-0.49| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 3, 2026 | $-0.49 | $-0.45 | — | $5.7M |
| Jul 30, 2026 | $-0.40 | $-0.45 | — | — |
| May 5, 2026 | $-0.39 | $-0.55 | — | — |
| Mar 5, 2026 | $-0.49 | $-0.50 | — | $7.5M |
| Oct 30, 2025 | $-0.45 | $-0.58 | — | $5.0M |
| Aug 5, 2025 | $-0.62 | $-0.56 | — | $7.5M |
| May 14, 2025 | $-0.62 | $-0.56 | — | $6.0M |
| Mar 6, 2025 | $-0.56 | $-0.44 | — | — |
News
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today reported its third-quarter 2026 financial results. “Lysophosphatidic acid 1 receptor (LPAR1) antagonism as a treatment approach for pulmonary fibrosis has exceptionally strong clinical validation with multiple trials successfully c.
Contineum Therapeutics, Inc. (CTNM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Contineum Therapeutics Inc. (NASDAQ:CTNM) stock plunged Monday following mixed Phase 3 trial results for Bristol Myers Squibb & Co.'s (NYSE:BMY) competing lung disease drug, admilparant.
Squarepoint Ops LLC lessened its position in shares of Contineum Therapeutics, Inc. (NASDAQ: CTNM) by 80.4% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 11,736 shares of the company's stock after selling 48,108 shares during the period. Squarepoint
Shares of Contineum Therapeutics, Inc. (NASDAQ: CTNM - Get Free Report) dropped 9.9% during mid-day trading on Tuesday after JonesTrading lowered their price target on the stock from $26.00 to $24.00. JonesTrading currently has a buy rating on the stock. Contineum Therapeutics traded as low as $13.08 and last traded at $13.3550. 77,867 shares changed hands
Contineum Therapeutics, Inc. (NASDAQ:CTNM) shares are trading lower on Tuesday as Phase 2 results from a key study disappoint.
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that the MOONLIGHT-1 trial did not achieve its primary efficacy endpoint. The trial evaluated improvement from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Day 5 compared with placebo.
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that management is scheduled to present at the 2026 Morgan Stanley Global Healthcare Conference on Tuesday, September 15th at 5:35 p.m. ET. An audio webcast of the fireside chat can be accessed on the Investors section of.